This is a high-risk, high-reward stock.In this video, I will cover the recent updates regarding Viking Therapeutics (VKTX 0.56%). Watch the short video to learn more, consider subscribing, and click the special offer link below.*Stock prices used were from the trading day of Jan. 3, 2025. The video was published on Jan. 4, 2025. ...

Market Dynamics - Viking Therapeutics' share price declined by 24% in December 2024 due to intensified competition in the pharmaceutical market [1] - Merck entered into a licensing deal with Hansoh Pharma for an investigational weight-loss drug HS-10535, posing a threat to Viking's VK2735 program [3] - The weight-loss drug market is highly lucrative with only two GLP-1 drugs approved in the US, indicating significant growth potential [6] Competitive Landscape - Merck secured exclusive global licensing rights to HS-10535, committing $112 million upfront and up to $1.9 billion in milestone payments and royalties [5] - Viking's VK2735, an oral obesity drug, is relatively advanced in development and has shown promising results in clinical trials [3][8] - VK2735 has a competitive advantage over injectable treatments like Novo Nordisk's Wegovy and Eli Lilly's Zepbound [4] Development Progress - HS-10535 is still in development and its efficacy remains uncertain, while VK2735 is closer to commercialization [7][8] - Viking's VK2735 is positioned as a potential go-to treatment due to its oral administration format [8]

It's been an excellent year for Viking Therapeutics (VKTX 2.19%), a mid-cap biotech company. Thanks to impressive mid-stage clinical results, its stock skyrocketed in February. And although it's down from the all-time highs it hit earlier this year, it remains one of the better performers in the industry over the past 12 months.However, Viking's shares recently dropped massively -- by more than 10% -- in one day. And the stock is down 24% in the past month. What exactly caused this recent decline? Should in ...

The weight-loss biotech Viking Therapeutics (VKTX 1.83%) saw its stock get absolutely slammed on Dec. 18, falling 18% as a result of a new move announced by Merck (MRK -1.48%).Given that Viking doesn't yet have any products approved for sale, is this the start of the end, or just a rough bump in the road?The market's fears are overblown, but not ungroundedFirst, let's get to the bottom of what Merck did to provoke Viking's stock into tumbling so much and so quickly.Merck just signed a licensing deal with a ...

News of a fresh licensing deal by a well-capitalized rival sent Viking Therapeutics (VKTX 1.83%) stock into something of a tailspin this week. According to data compiled by S&P Global Market Intelligence, the biotech's share price fell by just over 10% over the period as a result.Merck makes a moveThat news hit the headlines on Wednesday, with global pharmaceutical company Merck announcing that it had entered into an exclusive worldwide licensing arrangement for a GLP-1 obesity drug currently in development ...

Shares of Viking Therapeutics (VKTX) lost 18% yesterday after pharma giant Merck (MRK) announced its foray into the obesity space. On Wednesday, Merck announced that it has secured a licensing deal for China-based Hansoh Pharma's investigational weight-loss drug. More on MRK's Drug Deal Per the terms of the deal, Merck will obtain exclusive rights to develop and market HS-10535, a preclinical oral small-molecule GLP-1 receptor agonist targeting metabolic disorders, including obesity. Hansoh will receive an ...

Viking Therapeutics Inc. VKTX is nearing a pivotal moment as its stock hovers just above a potential death cross.This ominous technical pattern, where the 50-day moving average moves below the 200-day moving average, is often seen as a bearish signal. While not confirmed yet, the trajectory suggests growing pressure on the stock, which has struggled in recent months despite earlier rallies. Chart created using Benzinga ProRead Also: Biden Proposes Medicare, Medicaid Access For Popular Weight-Loss DrugsVKTX ...

Ken Griffin started the Citadel hedge fund in 1990. It's become so successful that his net worth has risen to a stunning $46 billion.In the third quarter, Griffin and Citadel more than tripled its stake in Viking Therapeutics (VKTX 1.86%). Griffin isn't the only one enthusiastic about this clinical-stage drugmaker. Wall Street analysts are sticking their necks out and predicting big gains around the corner.Recently, B. Riley analyst Mayank Mamtani initiated coverage of Viking Therapeutics with a buy rating. ...

It has been about a month since the last earnings report for Viking Therapeutics, Inc. (VKTX) . Shares have lost about 29.5% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Viking Therapeutics due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Narrower-Than-Expecte ...

Shares of Viking Therapeutics (VKTX) have lost nearly 17% in the past month, translating to about $1.2 billion in market value, compared with the industry’s 7.1% decline. The stock has also underperformed the sector and the S&P 500 during the same period, as shown in the chart below. VKTX’s shares are trading below the 50 and 200-day moving averages.VKTX Stock Underperforms Industry, Sector & S&P 500 Image Source: Zacks Investment ResearchThough this biotech’s progress with its obesity drug program has been ...